ACTR-21. MANAGEMENT OF OCULAR SIDE EFFECTS IN PATIENTS WITH EGFR-AMPLIFIED GLIOBLASTOMA RECEIVING DEPATUXIZUMAB MAFODOTIN

ABSTRACT: Abstract

BACKGROUND

Depatuxizumab mafodotin (depatux-m, formerly ABT-414), is an antibody-drug conjugate comprised of an EGFR-targeted antibody, a non-cleavable linker maleimidocaproyl, and the microtubule inhibitor monomethylauristatin F. Promising antitumor activity of depatux-m was observed in patients with glioblastoma (GBM) in Phase 12 studies. Dosage of depatux-m is limited by ocular side effects (OSE), such as blurred vision, dry eye, and photophobia from corneal epitheliopathy, which are generally reversible after dose reduction or drug discontinuation. This Phase 3b study evaluates depatux-m-related OSE management strategies used in depatux-m clinical trials.

METHODS

This open-label study will enroll approximately 90 patients with newly diagnosed, histologically

SUBMITTER: Kim S 

PROVIDER: S-EPMC6216179 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature